358 related articles for article (PubMed ID: 24064511)
1. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.
Rello J; Krenn CG; Locker G; Pilger E; Madl C; Balica L; Dugernier T; Laterre PF; Spapen H; Depuydt P; Vincent JL; Bogár L; Szabó Z; Völgyes B; Máñez R; Cakar N; Ramazanoglu A; Topeli A; Mastruzzo MA; Jasovich A; Remolif CG; Del Carmen Soria L; Andresen Hernandez MA; Ruiz Balart C; Krémer I; Molnár Z; von Sonnenburg F; Lyons A; Joannidis M; Burgmann H; Welte T; Klingler A; Hochreiter R; Westritschnig K
Crit Care; 2017 Feb; 21(1):22. PubMed ID: 28159015
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
Mansouri E; Gabelsberger J; Knapp B; Hundt E; Lenz U; Hungerer KD; Gilleland HE; Staczek J; Domdey H; von Specht BU
Infect Immun; 1999 Mar; 67(3):1461-70. PubMed ID: 10024596
[TBL] [Abstract][Full Text] [Related]
4. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
[TBL] [Abstract][Full Text] [Related]
5. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
6. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
7. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
[TBL] [Abstract][Full Text] [Related]
8. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
13. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
14. [Production of hybrid protein OprF-OprL of Pseudomonas aeruginosa].
Kaloshin AA; Mikhaĭlova NA; Leonova EI
Zh Mikrobiol Epidemiol Immunobiol; 2012; (3):35-43. PubMed ID: 22830272
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.
Adlbrecht C; Wurm R; Depuydt P; Spapen H; Lorente JA; Staudinger T; Creteur J; Zauner C; Meier-Hellmann A; Eller P; Laenen MV; Molnár Z; Várkonyi I; Schaaf B; Héjja M; Šrámek V; Schneider H; Kanesa-Thasan N; Eder-Lingelbach S; Klingler A; Dubischar K; Wressnigg N; Rello J
Crit Care; 2020 Mar; 24(1):74. PubMed ID: 32131866
[TBL] [Abstract][Full Text] [Related]
16. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
[TBL] [Abstract][Full Text] [Related]
17. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
18. [Study on Construction of Recombinant Bb-pGEX-
Liu X; Li WG; Luo GX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):13-17. PubMed ID: 29737082
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
Larbig M; Mansouri E; Freihorst J; Tümmler B; Köhler G; Domdey H; Knapp B; Hungerer KD; Hundt E; Gabelsberger J; von Specht BU
Vaccine; 2001 Mar; 19(17-19):2291-7. PubMed ID: 11257350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
